Technology | Computed Tomography (CT) | December 11, 2017

Philips Debuts IQon Elite Spectral CT Scanner at RSNA 2017

New configuration designed to enhance imaging for emergency/trauma care and oncology

Philips Debuts IQon Elite Spectral CT Scanner at RSNA 2017
 PhilipsIQonEliteSpectralCTbowelischemia

December 11, 2017 — At the 2017 Radiological Society of North America (RSNA) Annual Meeting, Philips unveiled the IQon Elite Spectral CT, designed to provide clinicians with increased diagnostic certainty in every scan. The system, a new configuration of the company's first spectral detector-based computed tomography (CT) scanner, debuts a suite of features that will enhance the clinical benefits of the IQon platform to improve diagnostic confidence while enhancing the patient experience, and supporting the needs of emergency/trauma and oncology care.    

This new configuration provides a number of enhanced features and benefits, including:

  • Enhanced diagnostic certainty - The IQon Elite’s faster reconstruction speeds and better visualization of bone marrow pathology enhance diagnostic confidence within emergency and trauma departments, providing the opportunity to reduce the need for subsequent scans. Its ability to estimate electron density provides enhanced tissue characterization, enabling a new level of diagnostic certainty for oncology clinicians and their patients.
  • Increased patient volume - IQon Elite has been shown to double patient throughput to 200 patients per day (based on a 16-hour clinical shift). This is an important benchmark for healthcare facilities experiencing a high volume of patients, especially in the emergency department where CT can be a commonly used imaging modality.
  • Enhanced clinical breadth – Its new radiation therapy planning couch and bariatric table top allow larger patients to be scanned with increased positioning controls.

The IQon Elite Spectral CT scanner will be available globally during the first quarter of 2018.

For more information: www.usa.philips.com/healthcare

Related Content

Infervision's newly FDA approved CT lung AI application sets a new standard
News | Artificial Intelligence | July 10, 2020
July 10, 2020 — Infervision announced U.S.
Artificial intelligence (AI)-assisted software was used to identify inflammatory tissues in lung and automatically segment inflammatory lesions. Three-dimensional image shows regions of COVID-19 pneumonia in lung through AI postprocessing. Image courtesy of the American Journal of Roentgenology (AJR)

Artificial intelligence (AI)-assisted software was used to identify inflammatory tissues in lung and automatically segment inflammatory lesions. Three-dimensional image shows regions of COVID-19 pneumonia in lung through AI postprocessing. Image courtesy of the American Journal of Roentgenology (AJR)

News | Coronavirus (COVID-19) | July 10, 2020
July 10, 2020 — An open-access Ameri
A lung CT of a COVID-19 patient, showing ground-glass opacities in the lung from COVID pneumonia. Image courtesy of John Kim.

A lung CT of a COVID-19 patient, showing ground-glass opacities in the lung from COVID pneumonia. Image courtesy of John Kim.

News | Coronavirus (COVID-19) | July 09, 2020
July 9, 2020 — With increased lung CT exam paradigms being used in the current...
World's largest radiation oncology meeting will offer full conference on interactive platform October 25-28, 2020
News | ASTRO | July 09, 2020
July 9, 2020 — Registration opens today for the American Society for Radiation Oncology's (...
Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.
Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault
Everything has room for improvement, right? Right. When it comes to cancer care, it is no different.
Proton therapy has evolved, and future predictions include smaller systems, more sophisticated proton dosimetry and devices that manipulate the proton beam
Feature | Proton Therapy | July 06, 2020 | By Minesh Mehta, M.D.
The field of proton...
This data represents wave 2 of a QuickPoLL survey conducted in partnership with an imagePRO panel created by The MarkeTech Group (TMTG), regarding the effects of COVID-19 on their business

Getty Images

Feature | Coronavirus (COVID-19) | July 01, 2020 | By Melinda Taschetta-Millane
Imaging Artificial Intelligence (AI) provider Qure.ai announced its first US FDA 510(k) clearance for its head CT scan product qER. The US Food and Drug Administration's decision covers four critical abnormalities identified by Qure.ai's emergency room product.
News | Artificial Intelligence | June 30, 2020
June 30, 2020 — Imaging Artificial Intelligence (AI) provider Qure.ai announced its first US FDA 510(k) clearance for
In new QuickPoLL survey on imaging during the pandemic, responses were tallied from around 170 radiology administrators and business managers, who are part of an imagePRO panel created by The MarkeTech Group (TMTG), regarding the effects of COVID-19 on their business. TMTG is a research firm specializing in the medical device, healthcare and pharmaceutical industries.
Feature | Coronavirus (COVID-19) | June 30, 2020 | By Melinda Taschetta-Millane